• Medical provider overview
• Benefits & eligibility
• Authorization & referrals
  • Referral and authorization guidelines
  • Advanced Imaging and musculoskeletal utilization management programs
  • Injectable medication program
  • Claim edits policy
  • Medical necessity criteria
  • MCG®
  • Site of care
• Patient care programs
  • Health coaching
  • Case management
• Join our network
  • Become a provider
  • Credentialing
  • Practitioner rights
  • Networks
  • Fraud prevention
  • FAQs
• Provider resources
  • Claims and appeals
  • Policies and manuals
  • Clinical guidelines and tools
  • Contact us
  • Behavioral health
  • Preventive services
  • Medicare compliance
  • Forms
  • Samples
  • Samples
  • Workshops
  • Provider news
  • OEBB Reference Price Program
• Patient resources
  • Moda Health Be Better tools
  • Health Coaching
  • Patients’ rights and responsibilities
• Pharmacy
  • Rx and therapeutics
    • recall
    • recall
    • recall
    • recall
    • recall
    • recall
    • recall
    • recall
  • Business partners
  • ArrayRx pharmacy solutions
  • Immunizations and vaccines
  • Preferred Drug Program
  • Pharmacy formularies
  • Pharmacy forms
• Quality of care

FDA warns about rare occurrence of serious liver injury with use of hepatitis C medicines Mavyret, Zepatier, and Vosevi in some patients with advanced liver disease

[08-28-2019] The Food and Drug Administration (FDA) has received reports that the use of Mavyret, Zepatier, or Vosevi to treat chronic hepatitis C in patients with moderate to severe liver impairment has resulted in rare cases of worsening liver function or liver failure. All these medicines contain a hepatitis C virus (HCV) protease inhibitor and are not indicated for use in patients with moderate to severe liver impairment. In most patients, symptoms resolved or new onset worsening of liver function improved after stopping the medicine. These medicines have been widely used and are safe and effective in patients with no or mild liver impairment.

In many of the reported cases, liver failure occurred in patients who had signs and symptoms of moderate to severe liver impairment (Child-Pugh B or C) or other serious liver problems and should not have been treated with these medicines. In some cases, patients were reported to have no cirrhosis or compensated cirrhosis with mild liver impairment (Child-Pugh A) despite having evidence of decreased platelets at baseline or an increase in the pressure within the portal vein that carries blood from the digestive organs to the liver. In addition, some cases had other significant pre-existing risk factors such as liver cancer, alcohol abuse, or serious medical illnesses associated with serious liver problems. These factors may have contributed to clinical worsening of liver function or liver failure during treatment with these hepatitis C medicines. In most cases, liver failure or decompensation typically occurred within the first 4 weeks of starting treatment. We will continue to monitor this safety concern and will communicate any new information to the public if it becomes available.

Mavyret, Zepatier, and Vosevi are FDA-approved to treat chronic hepatitis C in patients without liver impairment or with mild liver impairment (Child-Pugh A). Clinical trials in patients with compensated cirrhosis or mild liver impairment (Child-Pugh A) have shown that these medicines are well tolerated and highly effective. These medicines reduce the amount of HCV in the body by preventing it from multiplying, which over time leads to clearing the virus from the body, or HCV cure, which can prevent or limit liver damage from HCV. HCV is a contagious disease, and without treatment it can lead to serious liver problems, including cirrhosis, liver cancer, and death. When prescribed as indicated, these medicines continue to be safe and effective.

Health care professionals should continue to prescribe Mavyret, Zepatier, or Vosevi as indicated in the prescribing information for patients without liver impairment or with mild liver impairment (Child-Pugh A). Assess severity of liver disease at baseline and closely monitor for signs and symptoms of worsening liver function such as increases in liver enzymes, jaundice, ascites, encephalopathy, and variceal hemorrhage. Assessment of baseline liver disease and close monitoring are especially important in those with pre-existing significant liver problems or risk factors, such as hepatocellular carcinoma or alcohol abuse, which can also contribute to clinical worsening of liver function or liver failure during treatment. Discontinue these medicines in patients who develop signs and symptoms of liver decompensation or as clinically indicated. Mavyret and Zepatier should not be prescribed in patients with any history of prior hepatic decompensation. Vosevi is indicated for patients who have previously failed certain other HCV treatments and is not recommended in patients with any history of hepatic decompensation unless the benefits outweigh the risk of liver injury, liver failure or death.

Patients should be aware that the risk of serious liver injury is rare. However, you should contact your health care professional right away if you develop fatigue, weakness, loss of appetite, nausea and vomiting, yellow eyes or skin, or light-colored stools as these may be signs of liver injury. If you have liver impairment or other pre-existing risk factors that can worsen liver function such as a history of alcohol abuse, you should talk with your health care professional about the benefits and risks of the medicine. Do not stop taking these medicines without first talking with your health care professionals because stopping treatment early can lead to inadequate treatment, which could allow your HCV to come back. Over time, this could result in progression to severe liver disease and its complications, including cirrhosis, liver cancer, and death. These medicines have been widely used and are safe and effective in patients without liver impairment or in those with mild liver impairment for whom they are indicated.

We identified 63* cases of worsening liver function called liver decompensation with regimens Mavyret, Zepatier, and Vosevi to treat hepatitis C. Some of these cases led to liver failure and death. Most of these patients had moderate to severe liver impairment and should not have been prescribed these medicines. This number includes only cases submitted to FDA* or those found in the medical literature, so there may be additional cases about which we are unaware (see Data Summary). In 2018, an estimated 72,000 patients received dispensed prescriptions for Mavyret, Zepatier, or Vosevi from U.S. outpatient retail and mail-order/specialty pharmacies.
To help FDA track safety issues with medicines, report side effects involving Mavyret, Zepatier, Vosevi, or other medicines to the FDA MedWatch program, using the information in the “Contact FDA” box at the bottom of the page.

*The cases were reported to the FDA Adverse Event Reporting System (FAERS).

Moda Health Provider Network

Find a physician, pharmacy or clinic

Member Dashboard

Username Password

• Forgot your password
• Forgot your username
• Create an account

• Careers
• Customer Service
• Terms of use
• Privacy and Transparency Center
• Non-discrimination statement

Copyright © Moda Partners, Inc. All rights reserved.
Health plans provided by Moda Health Plan, Inc. Dental plans in Oregon provided by Oregon Dental Service, dba Delta Dental Plan of Oregon. Dental plans in Alaska provided by Delta Dental of Alaska.
This site is meant to help you learn about plans and healthcare for you and your family. This site is subject to change in order to comply with state and federal law, including the Affordable Care Act (ACA) and related regulations, and connectivity with the federal Marketplace. If questions regarding benefits arise, the summary of benefits and coverage document is the master resource.